Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Распространенность и прогностическое значение гастроэнтерологических проявлений COVID-19: данные Российской университетской клиники
Распространенность и прогностическое значение гастроэнтерологических проявлений COVID-19: данные Российской университетской клиники
Янушевич О.О., Маев И.В., Крихели Н.И., Левченко О.В., Рогова И.В., Заборовский А.В., Андреев Д.Н., Кебина А.Л., Бордин Д.С., Бакулин И.Г., Бакулина Н.В., Андреев Н.Г., Асадулин П.О., Багдасарян А.С., Девкота М.К., Еварницкая Н.Р., Крикунова О.В., Кучер С.А., Соколов Ф.С., Фоменко А.К., Харьковский В.А., Шарина И.А. Распространенность и прогностическое значение гастроэнтерологических проявлений COVID-19: данные Российской университетской клиники. Терапевтический архив. 2021; 93 (8): 853–861.
DOI: 10.26442/00403660.2021.08.200977
DOI: 10.26442/00403660.2021.08.200977
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Оценка распространенности и прогностического значения гастроэнтерологических проявлений у пациентов с COVID-19.
Материалы и методы. Проведено одноцентровое ретроспективное когортное исследование. Анализу подлежали только случаи с лабораторно подтвержденной детекцией РНК вируса SARS-CoV-2 с помощью полимеразной цепной реакции в образцах оро-/назофарингеального мазка. Из общего реестра ретроспективных данных были исключены пациенты с документированной (по анамнестическим данным и/или по данным обследования в период госпитализации) органической патологией со стороны желудочно-кишечного тракта (ЖКТ) и/или гепатобилиарной системы, злокачественными новообразованиями любой локализации, а также беременные пациентки. Итоговая когорта была разделена на две группы в зависимости от наличия гастроэнтерологической симптоматики: COVID-19 с симптомами со стороны ЖКТ (случаи) и COVID-19 без симптомов со стороны ЖКТ (контроль).
Результаты. Итоговую выборку составили 3764 пациента, включая 2108 (56%) женщин и 1656 (44%) мужчин. Средний возраст включенных в анализ субъектов составил 58,0 года (95% доверительный интервал – ДИ 48,6–63,0). В исследуемой когорте гастроэнтерологические проявления (изолированно или в сочетании) были зарегистрированы у 885 (23,51%) пациентов. Расчет отношения шансов (ОШ) неблагоприятных и летальных исходов между анализируемыми группами продемонстрировал, что наличие гастроэнтерологической симптоматики значимо повышает шансы летального исхода в когорте пациентов пожилого и старческого возраста (ОШ 1,6817, 95% ДИ 1,0335–2,7364; p=0,0364), детерминирует более высокий риск госпитализации или перевода в отделение реанимации и интенсивной терапии (ОШ 1,2959, 95% ДИ 1,0547–1,5922; p=0,0136), развития острого респираторного дистресс-синдрома (ОШ 1,5952, 95% ДИ 1,3164–1,9329; p<0,0001), а также необходимость в проведении искусственной вентиляции легких (ОШ 1,2849, 95% ДИ 1,077–1,5329; p=0,0054).
Заключение. Настоящее исследование продемонстрировало, что гастроэнтерологическая симптоматика выявляется примерно у каждого четвертого больного, инфицированного вирусом SARS-CoV-2, и мультиплицирует риск неблагоприятных и жизнеугрожающих осложнений COVID-19.
Ключевые слова: коронавирус, COVID-19, SARS-CoV-2, желудочно-кишечный тракт, диарея, тошнота, рвота, абдоминальная боль
Materials and methods. A single-center retrospective cohort study was carried out. Only cases with laboratory confirmed detection of SARS-CoV-2 virus RNA using polymerase chain reaction in oro-/nasopharyngeal smear samples were subject to analysis. Patients with documented (according to anamnestic data and/or according to examination data during hospitalization) organic pathology of the gastrointestinal tract (GIT) and/or hepatobiliary system, malignant neoplasms of any localization, as well as pregnant patients were excluded from the general register of retrospective data. The final cohort was divided into two groups depending on the presence of gastrointestinal symptoms: COVID-19 with gastrointestinal symptoms (cases) and COVID-19 without gastrointestinal symptoms (control).
Results. The final sample consisted of 3764 patients, including 2108 (56%) women and 1656 (44%) men. The average age of the subjects included in the analysis was 58.0 years (95% confidence interval – CI 48.6–63.0). In the study cohort, gastroenterological manifestations (alone or in combination) were recorded in 885 (23.51%) patients. Calculation of the odds ratio (OR) of unfavorable and lethal outcomes between the analyzed groups showed that the presence of gastroenterological symptoms significantly increases the chances of lethal outcome in a cohort of elderly and senile patients (OR 1.6817, 95% CI 1.0335–2.7364; p=0.0364), determines a higher risk of hospitalization or transfer to the intensive care unit (OR 1.2959, 95% CI 1.0547–1.5922; p=0.0136), development of acute respiratory distress syndrome (OR 1.5952, 95% CI 1.3164–1.9329; p<0.0001), as well as the need for mechanical ventilation (OR 1.2849, 95% CI 1.077–1.5329; p=0.0054).
Conclusion. The present study has demonstrated that gastroenterological symptoms are detected in about one in four patients infected with the SARS-CoV-2 virus and multiply the risk of adverse and life-threatening complications of COVID-19.
Keywords: coronavirus, COVID-19, SARS-CoV-2, gastrointestinal tract, diarrhea, nausea, vomiting, abdominal pain
Материалы и методы. Проведено одноцентровое ретроспективное когортное исследование. Анализу подлежали только случаи с лабораторно подтвержденной детекцией РНК вируса SARS-CoV-2 с помощью полимеразной цепной реакции в образцах оро-/назофарингеального мазка. Из общего реестра ретроспективных данных были исключены пациенты с документированной (по анамнестическим данным и/или по данным обследования в период госпитализации) органической патологией со стороны желудочно-кишечного тракта (ЖКТ) и/или гепатобилиарной системы, злокачественными новообразованиями любой локализации, а также беременные пациентки. Итоговая когорта была разделена на две группы в зависимости от наличия гастроэнтерологической симптоматики: COVID-19 с симптомами со стороны ЖКТ (случаи) и COVID-19 без симптомов со стороны ЖКТ (контроль).
Результаты. Итоговую выборку составили 3764 пациента, включая 2108 (56%) женщин и 1656 (44%) мужчин. Средний возраст включенных в анализ субъектов составил 58,0 года (95% доверительный интервал – ДИ 48,6–63,0). В исследуемой когорте гастроэнтерологические проявления (изолированно или в сочетании) были зарегистрированы у 885 (23,51%) пациентов. Расчет отношения шансов (ОШ) неблагоприятных и летальных исходов между анализируемыми группами продемонстрировал, что наличие гастроэнтерологической симптоматики значимо повышает шансы летального исхода в когорте пациентов пожилого и старческого возраста (ОШ 1,6817, 95% ДИ 1,0335–2,7364; p=0,0364), детерминирует более высокий риск госпитализации или перевода в отделение реанимации и интенсивной терапии (ОШ 1,2959, 95% ДИ 1,0547–1,5922; p=0,0136), развития острого респираторного дистресс-синдрома (ОШ 1,5952, 95% ДИ 1,3164–1,9329; p<0,0001), а также необходимость в проведении искусственной вентиляции легких (ОШ 1,2849, 95% ДИ 1,077–1,5329; p=0,0054).
Заключение. Настоящее исследование продемонстрировало, что гастроэнтерологическая симптоматика выявляется примерно у каждого четвертого больного, инфицированного вирусом SARS-CoV-2, и мультиплицирует риск неблагоприятных и жизнеугрожающих осложнений COVID-19.
Ключевые слова: коронавирус, COVID-19, SARS-CoV-2, желудочно-кишечный тракт, диарея, тошнота, рвота, абдоминальная боль
________________________________________________
Materials and methods. A single-center retrospective cohort study was carried out. Only cases with laboratory confirmed detection of SARS-CoV-2 virus RNA using polymerase chain reaction in oro-/nasopharyngeal smear samples were subject to analysis. Patients with documented (according to anamnestic data and/or according to examination data during hospitalization) organic pathology of the gastrointestinal tract (GIT) and/or hepatobiliary system, malignant neoplasms of any localization, as well as pregnant patients were excluded from the general register of retrospective data. The final cohort was divided into two groups depending on the presence of gastrointestinal symptoms: COVID-19 with gastrointestinal symptoms (cases) and COVID-19 without gastrointestinal symptoms (control).
Results. The final sample consisted of 3764 patients, including 2108 (56%) women and 1656 (44%) men. The average age of the subjects included in the analysis was 58.0 years (95% confidence interval – CI 48.6–63.0). In the study cohort, gastroenterological manifestations (alone or in combination) were recorded in 885 (23.51%) patients. Calculation of the odds ratio (OR) of unfavorable and lethal outcomes between the analyzed groups showed that the presence of gastroenterological symptoms significantly increases the chances of lethal outcome in a cohort of elderly and senile patients (OR 1.6817, 95% CI 1.0335–2.7364; p=0.0364), determines a higher risk of hospitalization or transfer to the intensive care unit (OR 1.2959, 95% CI 1.0547–1.5922; p=0.0136), development of acute respiratory distress syndrome (OR 1.5952, 95% CI 1.3164–1.9329; p<0.0001), as well as the need for mechanical ventilation (OR 1.2849, 95% CI 1.077–1.5329; p=0.0054).
Conclusion. The present study has demonstrated that gastroenterological symptoms are detected in about one in four patients infected with the SARS-CoV-2 virus and multiply the risk of adverse and life-threatening complications of COVID-19.
Keywords: coronavirus, COVID-19, SARS-CoV-2, gastrointestinal tract, diarrhea, nausea, vomiting, abdominal pain
Полный текст
Список литературы
1. Маев И.В., Шпектор А.В., Васильева Е.Ю., и др. Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления. Терапевтический архив. 2020;92(8):4-11 [Maev IV, Shpektor AV, Vasilyeva EYu, et al. Novel coronavirus infection COVID-19: extrapulmonary manifestations. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(8):4-11 (in Russian)]. DOI:10.26442/00403660.2020.08.000767
2. Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. DOI:10.1056/NEJMoa2001017
3. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83(3):217-20. DOI:10.1097/JCMA.0000000000000270
4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. DOI:10.1016/j.jaut.2020.102433
5. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. Available at: https://ourworldindata.org/coronavirus. Accessed: 24.05.2021.
6. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. DOI:10.1016/j.jinf.2020.04.021
7. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744-8. DOI:10.1111/jgh.15047
8. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-8. DOI:10.1126/science.abb2762
9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.e8. DOI:10.1016/j.cell.2020.02.052
10. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3‐11
11. Taka E, Yilmaz SZ, Golcuk M, et al. Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. J Phys Chem B. 2021. DOI:10.1021/acs.jpcb.1c02048
12. Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548-51. DOI:10.1002/jmv.25722
13. Carcaterra M, Caruso C. Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory. Med Hypotheses. 2021;146:110412. DOI:10.1016/j.mehy.2020.110412
14. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. DOI:10.1097/JCMA.0000000000000319
15. Su S, Shen J, Zhu L, et al. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol. 2020;13:1756284820934626. DOI:10.1177/1756284820934626
16. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843-51. DOI:10.1111/apt.15731
17. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831-3.e3. DOI:10.1053/j.gastro.2020.02.055
18. Mandal A, Konala VM, Adapa S, et al. Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications. Cureus. 2020;12(6):e8750. DOI:10.7759/cureus.8750
19. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020. DOI:10.1016/S2468-1253(20)30126-6
20. Elshazli RM, Kline A, Elgaml A, et al. Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves. J Med Virol. 2021;93(5):2740-68. DOI:10.1002/jmv.26836
21. Cruz VMA, Santos E, Cervantes MA, Juárez LM. COVID-19, a worldwide public health emergency. Rev Clin Esp (Barc). 2021;221(1):55-61. DOI:10.1016/j.rceng.2020.03.001
22. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021;97(1147):312-20. DOI:10.1136/postgradmedj-2020-138577
23. Бордин Д.С., Кирюкова М.А., Шенгелия М.И., Колбасников С.В. Инфекция COVID-19 и органы пищеварения. Эффективная фармакотерапия. 2020;16(15):12-6 [Bordin DS, Kiryukova MA, Shengelia MI, Kolbasnikov SV. COVID-19 infection and digestive organs. Effective pharmacotherapy. 2020;16(15):12-6 (in Russian)]. DOI:10.33978/2307-3586-2020-16-15-12-16
24. Шенгелия М.И., Иванова В.А., Вечорко В.И., и др. Гастроэнтерологические проявления у пациентов с инфекцией COVID-19. Эффективная фармакотерапия. 2020;16(30):44-9 [Shengelia MI, Ivanova VA, Vechorko VI, et al. Gastroenterological manifestations in patients with COVID-19 infection. Effective pharmacotherapy. 2020;16(30):44-9 (in Russian)]. DOI:10.33978/2307-3586-2020-16-30-44-49
25. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9. DOI:10.1136/gutjnl-2020-320926
26. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020;115(5):766-73. DOI:10.14309/ajg.0000000000000620
27. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. DOI:10.1111/all.14238
28. Redd WD, Zhou JC, Hathorn KE, et al. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study. Gastroenterology. 2020;159(2):765-7.e2. DOI:10.1053/j.gastro.2020.04.045
29. Ramachandran P, Onukogu I, Ghanta S, et al. Gastrointestinal Symptoms and Outcomes in Hospitalized Coronavirus Disease 2019 Patients. Dig Dis. 2020;38(5):373-9. DOI:10.1159/000509774
30. Oshima T, Siah KTH, Yoshimoto T, et al. Impacts of the COVID2019 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2020:10.1111/jgh.15346. DOI:10.1111/jgh.15346
31. Bishehsari F, Adnan D, Deshmukh A, et al. Gastrointestinal Symptoms Predict the Outcomes From COVID-19 Infection. J Clin Gastroenterol. 2021. DOI:10.1097/MCG.0000000000001513
32. Adnan D, Deshmukh A, Khan SR, et al. Gastrointestinal Symptoms Predict the Outcomes of COVID-19 Infection. Am J Gastroenterol. 2020;115:S685-S686. DOI:10.14309/01.ajg.0000707480.23480.66
33. Zawada AE, Moszak M, Skrzypczak D, Grzymisławski M. Gastrointestinal complications in patients with diabetes mellitus. Adv Clin Exp Med. 2018;27(4):567-72. DOI:10.17219/acem/67961
34. Kurniawan AH, Suwandi BH, Kholili U. Diabetic Gastroenteropathy:
A Complication of Diabetes Mellitus. Acta Med Indones. 2019;51(3):263-71.
35. Chen R, Yu YL, Li W, et al. Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. Front Med (Lausanne). 2020;7:608259. DOI:10.3389/fmed.2020.608259
36. Li X, Zhong X, Wang Y, et al. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS One. 2021;16(5):e0250602. DOI:10.1371/journal.pone.0250602
37. Du P, Li D, Wang A, et al. A Systematic Review and Meta-Analysis of Risk Factors Associated with Severity and Death in COVID-19 Patients. Can J Infect Dis Med Microbiol. 2021;2021:6660930. DOI:10.1155/2021/6660930
2. Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. DOI:10.1056/NEJMoa2001017
3. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83(3):217-20. DOI:10.1097/JCMA.0000000000000270
4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. DOI:10.1016/j.jaut.2020.102433
5. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. Available at: https://ourworldindata.org/coronavirus. Accessed: 24.05.2021.
6. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. DOI:10.1016/j.jinf.2020.04.021
7. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744-8. DOI:10.1111/jgh.15047
8. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-8. DOI:10.1126/science.abb2762
9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.e8. DOI:10.1016/j.cell.2020.02.052
10. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3‐11
11. Taka E, Yilmaz SZ, Golcuk M, et al. Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. J Phys Chem B. 2021. DOI:10.1021/acs.jpcb.1c02048
12. Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548-51. DOI:10.1002/jmv.25722
13. Carcaterra M, Caruso C. Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory. Med Hypotheses. 2021;146:110412. DOI:10.1016/j.mehy.2020.110412
14. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. DOI:10.1097/JCMA.0000000000000319
15. Su S, Shen J, Zhu L, et al. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol. 2020;13:1756284820934626. DOI:10.1177/1756284820934626
16. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843-51. DOI:10.1111/apt.15731
17. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831-3.e3. DOI:10.1053/j.gastro.2020.02.055
18. Mandal A, Konala VM, Adapa S, et al. Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications. Cureus. 2020;12(6):e8750. DOI:10.7759/cureus.8750
19. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020. DOI:10.1016/S2468-1253(20)30126-6
20. Elshazli RM, Kline A, Elgaml A, et al. Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves. J Med Virol. 2021;93(5):2740-68. DOI:10.1002/jmv.26836
21. Cruz VMA, Santos E, Cervantes MA, Juárez LM. COVID-19, a worldwide public health emergency. Rev Clin Esp (Barc). 2021;221(1):55-61. DOI:10.1016/j.rceng.2020.03.001
22. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021;97(1147):312-20. DOI:10.1136/postgradmedj-2020-138577
23. Bordin DS, Kiryukova MA, Shengelia MI, Kolbasnikov SV. COVID-19 infection and digestive organs. Effective pharmacotherapy. 2020;16(15):12-6 (in Russian)
DOI:10.33978/2307-3586-2020-16-15-12-16
24. Shengelia MI, Ivanova VA, Vechorko VI, et al. Gastroenterological manifestations in patients with COVID-19 infection. Effective pharmacotherapy. 2020;16(30):44-9 (in Russian) DOI:10.33978/2307-3586-2020-16-30-44-49
25. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9. DOI:10.1136/gutjnl-2020-320926
26. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020;115(5):766-73. DOI:10.14309/ajg.0000000000000620
27. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. DOI:10.1111/all.14238
28. Redd WD, Zhou JC, Hathorn KE, et al. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study. Gastroenterology. 2020;159(2):765-7.e2. DOI:10.1053/j.gastro.2020.04.045
29. Ramachandran P, Onukogu I, Ghanta S, et al. Gastrointestinal Symptoms and Outcomes in Hospitalized Coronavirus Disease 2019 Patients. Dig Dis. 2020;38(5):373-9. DOI:10.1159/000509774
30. Oshima T, Siah KTH, Yoshimoto T, et al. Impacts of the COVID2019 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2020:10.1111/jgh.15346. DOI:10.1111/jgh.15346
31. Bishehsari F, Adnan D, Deshmukh A, et al. Gastrointestinal Symptoms Predict the Outcomes From COVID-19 Infection. J Clin Gastroenterol. 2021. DOI:10.1097/MCG.0000000000001513
32. Adnan D, Deshmukh A, Khan SR, et al. Gastrointestinal Symptoms Predict the Outcomes of COVID-19 Infection. Am J Gastroenterol. 2020;115:S685-S686. DOI:10.14309/01.ajg.0000707480.23480.66
33. Zawada AE, Moszak M, Skrzypczak D, Grzymisławski M. Gastrointestinal complications in patients with diabetes mellitus. Adv Clin Exp Med. 2018;27(4):567-72. DOI:10.17219/acem/67961
34. Kurniawan AH, Suwandi BH, Kholili U. Diabetic Gastroenteropathy:
A Complication of Diabetes Mellitus. Acta Med Indones. 2019;51(3):263-71.
35. Chen R, Yu YL, Li W, et al. Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. Front Med (Lausanne). 2020;7:608259. DOI:10.3389/fmed.2020.608259
36. Li X, Zhong X, Wang Y, et al. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS One. 2021;16(5):e0250602. DOI:10.1371/journal.pone.0250602
37. Du P, Li D, Wang A, et al. A Systematic Review and Meta-Analysis of Risk Factors Associated with Severity and Death in COVID-19 Patients. Can J Infect Dis Med Microbiol. 2021;2021:6660930. DOI:10.1155/2021/6660930
2. Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. DOI:10.1056/NEJMoa2001017
3. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83(3):217-20. DOI:10.1097/JCMA.0000000000000270
4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. DOI:10.1016/j.jaut.2020.102433
5. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. Available at: https://ourworldindata.org/coronavirus. Accessed: 24.05.2021.
6. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. DOI:10.1016/j.jinf.2020.04.021
7. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744-8. DOI:10.1111/jgh.15047
8. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-8. DOI:10.1126/science.abb2762
9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.e8. DOI:10.1016/j.cell.2020.02.052
10. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3‐11
11. Taka E, Yilmaz SZ, Golcuk M, et al. Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. J Phys Chem B. 2021. DOI:10.1021/acs.jpcb.1c02048
12. Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548-51. DOI:10.1002/jmv.25722
13. Carcaterra M, Caruso C. Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory. Med Hypotheses. 2021;146:110412. DOI:10.1016/j.mehy.2020.110412
14. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. DOI:10.1097/JCMA.0000000000000319
15. Su S, Shen J, Zhu L, et al. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol. 2020;13:1756284820934626. DOI:10.1177/1756284820934626
16. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843-51. DOI:10.1111/apt.15731
17. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831-3.e3. DOI:10.1053/j.gastro.2020.02.055
18. Mandal A, Konala VM, Adapa S, et al. Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications. Cureus. 2020;12(6):e8750. DOI:10.7759/cureus.8750
19. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020. DOI:10.1016/S2468-1253(20)30126-6
20. Elshazli RM, Kline A, Elgaml A, et al. Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves. J Med Virol. 2021;93(5):2740-68. DOI:10.1002/jmv.26836
21. Cruz VMA, Santos E, Cervantes MA, Juárez LM. COVID-19, a worldwide public health emergency. Rev Clin Esp (Barc). 2021;221(1):55-61. DOI:10.1016/j.rceng.2020.03.001
22. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021;97(1147):312-20. DOI:10.1136/postgradmedj-2020-138577
23. Бордин Д.С., Кирюкова М.А., Шенгелия М.И., Колбасников С.В. Инфекция COVID-19 и органы пищеварения. Эффективная фармакотерапия. 2020;16(15):12-6 [Bordin DS, Kiryukova MA, Shengelia MI, Kolbasnikov SV. COVID-19 infection and digestive organs. Effective pharmacotherapy. 2020;16(15):12-6 (in Russian)]. DOI:10.33978/2307-3586-2020-16-15-12-16
24. Шенгелия М.И., Иванова В.А., Вечорко В.И., и др. Гастроэнтерологические проявления у пациентов с инфекцией COVID-19. Эффективная фармакотерапия. 2020;16(30):44-9 [Shengelia MI, Ivanova VA, Vechorko VI, et al. Gastroenterological manifestations in patients with COVID-19 infection. Effective pharmacotherapy. 2020;16(30):44-9 (in Russian)]. DOI:10.33978/2307-3586-2020-16-30-44-49
25. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9. DOI:10.1136/gutjnl-2020-320926
26. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020;115(5):766-73. DOI:10.14309/ajg.0000000000000620
27. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. DOI:10.1111/all.14238
28. Redd WD, Zhou JC, Hathorn KE, et al. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study. Gastroenterology. 2020;159(2):765-7.e2. DOI:10.1053/j.gastro.2020.04.045
29. Ramachandran P, Onukogu I, Ghanta S, et al. Gastrointestinal Symptoms and Outcomes in Hospitalized Coronavirus Disease 2019 Patients. Dig Dis. 2020;38(5):373-9. DOI:10.1159/000509774
30. Oshima T, Siah KTH, Yoshimoto T, et al. Impacts of the COVID2019 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2020:10.1111/jgh.15346. DOI:10.1111/jgh.15346
31. Bishehsari F, Adnan D, Deshmukh A, et al. Gastrointestinal Symptoms Predict the Outcomes From COVID-19 Infection. J Clin Gastroenterol. 2021. DOI:10.1097/MCG.0000000000001513
32. Adnan D, Deshmukh A, Khan SR, et al. Gastrointestinal Symptoms Predict the Outcomes of COVID-19 Infection. Am J Gastroenterol. 2020;115:S685-S686. DOI:10.14309/01.ajg.0000707480.23480.66
33. Zawada AE, Moszak M, Skrzypczak D, Grzymisławski M. Gastrointestinal complications in patients with diabetes mellitus. Adv Clin Exp Med. 2018;27(4):567-72. DOI:10.17219/acem/67961
34. Kurniawan AH, Suwandi BH, Kholili U. Diabetic Gastroenteropathy:
A Complication of Diabetes Mellitus. Acta Med Indones. 2019;51(3):263-71.
35. Chen R, Yu YL, Li W, et al. Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. Front Med (Lausanne). 2020;7:608259. DOI:10.3389/fmed.2020.608259
36. Li X, Zhong X, Wang Y, et al. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS One. 2021;16(5):e0250602. DOI:10.1371/journal.pone.0250602
37. Du P, Li D, Wang A, et al. A Systematic Review and Meta-Analysis of Risk Factors Associated with Severity and Death in COVID-19 Patients. Can J Infect Dis Med Microbiol. 2021;2021:6660930. DOI:10.1155/2021/6660930
________________________________________________
2. Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. DOI:10.1056/NEJMoa2001017
3. Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. J Chin Med Assoc. 2020;83(3):217-20. DOI:10.1097/JCMA.0000000000000270
4. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. DOI:10.1016/j.jaut.2020.102433
5. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. Available at: https://ourworldindata.org/coronavirus. Accessed: 24.05.2021.
6. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25. DOI:10.1016/j.jinf.2020.04.021
7. Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744-8. DOI:10.1111/jgh.15047
8. Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-8. DOI:10.1126/science.abb2762
9. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.e8. DOI:10.1016/j.cell.2020.02.052
10. Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3‐11
11. Taka E, Yilmaz SZ, Golcuk M, et al. Critical Interactions Between the SARS-CoV-2 Spike Glycoprotein and the Human ACE2 Receptor. J Phys Chem B. 2021. DOI:10.1021/acs.jpcb.1c02048
12. Sun P, Lu X, Xu C, et al. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548-51. DOI:10.1002/jmv.25722
13. Carcaterra M, Caruso C. Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory. Med Hypotheses. 2021;146:110412. DOI:10.1016/j.mehy.2020.110412
14. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020. DOI:10.1097/JCMA.0000000000000319
15. Su S, Shen J, Zhu L, et al. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol. 2020;13:1756284820934626. DOI:10.1177/1756284820934626
16. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843-51. DOI:10.1111/apt.15731
17. Xiao F, Tang M, Zheng X, et al. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831-3.e3. DOI:10.1053/j.gastro.2020.02.055
18. Mandal A, Konala VM, Adapa S, et al. Gastrointestinal Manifestations in COVID-19 Infection and Its Practical Applications. Cureus. 2020;12(6):e8750. DOI:10.7759/cureus.8750
19. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020. DOI:10.1016/S2468-1253(20)30126-6
20. Elshazli RM, Kline A, Elgaml A, et al. Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves. J Med Virol. 2021;93(5):2740-68. DOI:10.1002/jmv.26836
21. Cruz VMA, Santos E, Cervantes MA, Juárez LM. COVID-19, a worldwide public health emergency. Rev Clin Esp (Barc). 2021;221(1):55-61. DOI:10.1016/j.rceng.2020.03.001
22. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. 2021;97(1147):312-20. DOI:10.1136/postgradmedj-2020-138577
23. Bordin DS, Kiryukova MA, Shengelia MI, Kolbasnikov SV. COVID-19 infection and digestive organs. Effective pharmacotherapy. 2020;16(15):12-6 (in Russian)
DOI:10.33978/2307-3586-2020-16-15-12-16
24. Shengelia MI, Ivanova VA, Vechorko VI, et al. Gastroenterological manifestations in patients with COVID-19 infection. Effective pharmacotherapy. 2020;16(30):44-9 (in Russian) DOI:10.33978/2307-3586-2020-16-30-44-49
25. Jin X, Lian JS, Hu JH, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9. DOI:10.1136/gutjnl-2020-320926
26. Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020;115(5):766-73. DOI:10.14309/ajg.0000000000000620
27. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. DOI:10.1111/all.14238
28. Redd WD, Zhou JC, Hathorn KE, et al. Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study. Gastroenterology. 2020;159(2):765-7.e2. DOI:10.1053/j.gastro.2020.04.045
29. Ramachandran P, Onukogu I, Ghanta S, et al. Gastrointestinal Symptoms and Outcomes in Hospitalized Coronavirus Disease 2019 Patients. Dig Dis. 2020;38(5):373-9. DOI:10.1159/000509774
30. Oshima T, Siah KTH, Yoshimoto T, et al. Impacts of the COVID2019 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2020:10.1111/jgh.15346. DOI:10.1111/jgh.15346
31. Bishehsari F, Adnan D, Deshmukh A, et al. Gastrointestinal Symptoms Predict the Outcomes From COVID-19 Infection. J Clin Gastroenterol. 2021. DOI:10.1097/MCG.0000000000001513
32. Adnan D, Deshmukh A, Khan SR, et al. Gastrointestinal Symptoms Predict the Outcomes of COVID-19 Infection. Am J Gastroenterol. 2020;115:S685-S686. DOI:10.14309/01.ajg.0000707480.23480.66
33. Zawada AE, Moszak M, Skrzypczak D, Grzymisławski M. Gastrointestinal complications in patients with diabetes mellitus. Adv Clin Exp Med. 2018;27(4):567-72. DOI:10.17219/acem/67961
34. Kurniawan AH, Suwandi BH, Kholili U. Diabetic Gastroenteropathy:
A Complication of Diabetes Mellitus. Acta Med Indones. 2019;51(3):263-71.
35. Chen R, Yu YL, Li W, et al. Gastrointestinal Symptoms Associated With Unfavorable Prognosis of COVID-19 Patients: A Retrospective Study. Front Med (Lausanne). 2020;7:608259. DOI:10.3389/fmed.2020.608259
36. Li X, Zhong X, Wang Y, et al. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS One. 2021;16(5):e0250602. DOI:10.1371/journal.pone.0250602
37. Du P, Li D, Wang A, et al. A Systematic Review and Meta-Analysis of Risk Factors Associated with Severity and Death in COVID-19 Patients. Can J Infect Dis Med Microbiol. 2021;2021:6660930. DOI:10.1155/2021/6660930
Авторы
О.О. Янушевич1, И.В. Маев1, Н.И. Крихели1, О.В. Левченко1, И.В. Рогова1, А.В. Заборовский1, Д.Н. Андреев*1, А.Л. Кебина1, Д.С. Бордин1–3, И.Г. Бакулин4, Н.В. Бакулина4, Н.Г. Андреев1, П.О. Асадулин1, А.С. Багдасарян1, М.К. Девкота1, Н.Р. Еварницкая1, О.В. Крикунова1, С.А. Кучер1, Ф.С. Соколов1, А.К. Фоменко1, В.А. Харьковский1, И.А. Шарина1
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России,
Москва, Россия;
2 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы,
Москва, Россия;
3 ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России, Тверь, Россия;
4 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия
*dna-mit8@mail.ru
1 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
2 Loginov Moscow Clinical Scientific Centre, Moscow, Russia;
3 Tver State Medical University, Tver, Russia;
4 Mechnikov North-Western State Medical University, Saint Petersburg, Russia
*dna-mit8@mail.ru
1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России,
Москва, Россия;
2 ГБУЗ «Московский клинический научно-практический центр им. А.С. Логинова» Департамента здравоохранения г. Москвы,
Москва, Россия;
3 ФГБОУ ВО «Тверской государственный медицинский университет» Минздрава России, Тверь, Россия;
4 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия
*dna-mit8@mail.ru
________________________________________________
1 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
2 Loginov Moscow Clinical Scientific Centre, Moscow, Russia;
3 Tver State Medical University, Tver, Russia;
4 Mechnikov North-Western State Medical University, Saint Petersburg, Russia
*dna-mit8@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.